Patents by Inventor Robert Henk Henning
Robert Henk Henning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230330060Abstract: The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment of heart failure with reduced ejection fraction (HFrEF). Specifically, the present invention relates to chromanol compounds chosen from S-(6-hydroxy-2,5,7,8-tetramethylchroman-2yl)(piperazin-1-yl)methanone and S-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: September 21, 2021Publication date: October 19, 2023Inventors: Robert Henk HENNING, Adrianus Cornelis VAN DER GRAAF, Guido KRENNING, Lucas Moritz WIGGENHAUSER
-
Patent number: 11730741Abstract: The present invention relates to the (S) enantiomeric form of certain 6-chromanol derivatives for use as a medicament. Especially, the present invention relates to the (S) enantiomeric form of a 6-chromanol derivative for use as a medicament wherein said 6-chromanol derivative is chosen from the group consisting of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts or bases thereof and pharmaceutically acceptable salts thereof.Type: GrantFiled: August 23, 2018Date of Patent: August 22, 2023Assignee: SULFATEQ B.V.Inventors: Robert Henk Henning, Gerrit Jan Willem Euverink, Guido Krenning, Adrianus Cornelis Van der Graaf
-
Publication number: 20230202997Abstract: The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment of sepsis and sepsis-induced organ dysfunction. Specifically, the present invention relates to chromanol compounds chosen from S-(6-hydroxy-2,5,7,8-tetramethylchroman-2yl)(piperazin-1-yl)methanone and S-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 2, 2021Publication date: June 29, 2023Inventors: Hjalmar Roland BOUMA, Guido Krenning, Robert Henk HENNING, Adrianus Cornelis VAN DER GRAAF
-
Publication number: 20230052152Abstract: The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment of Alzheimer's disease and/or for improving memory function and/or reducing plaque load. Specifically, the present invention relates to chromanol compounds chosen from (6-hydroxy-2,5,7,8-tetramethylchroman-2yl)(piperazin-1-5 yl)methanone, ((S)-6-hy-droxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride and S-(6-hydroxy-2,5,7,8-tetramethylchro-man-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: December 11, 2020Publication date: February 16, 2023Inventors: Robert Henk HENNING, Adrianus Cornelis VAN DER GRAAF, Guido KRENNING, Daniël Henri SWART, Christina Françoise DE VEIJ MESTDAGH, Pieter Cornelis VOGELAAR
-
Publication number: 20210128523Abstract: The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions. Specifically, the present invention relates to (2R) enantiomeric form of a 6-chromanol derivative for use in the prophylactic or treatment of vasoconstriction related disorders or conditions. A preferred 6-chromanol derivative is (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 23, 2018Publication date: May 6, 2021Inventors: Robert Henk Henning, Gerrit Jan Willem Euverink, Guido Krenning, Adrianus Cornelis Van der Graaf
-
Publication number: 20210024485Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.Type: ApplicationFiled: June 8, 2020Publication date: January 28, 2021Inventors: Adrianus Cornelis van der GRAAF, Robert Henk HENNING, Leo Edwin DEELMAN, Gerrit Jan Willem EUVERINK
-
Publication number: 20200206235Abstract: The present invention relates to the (S) enantiomeric form of certain 6-chromanol derivatives for use as a medicament. Especially, the present invention relates to the (S) enantiomeric form of a 6-chromanol derivative for use as a medicament wherein said 6-chromanol derivative is chosen from the group consisting of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts or bases thereof and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 23, 2018Publication date: July 2, 2020Inventors: Robert Henk Henning, Gerrit Jan Willem Euverink, Guido Krenning, Adrianus Cornelis Van der Graaf
-
Patent number: 10676452Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.Type: GrantFiled: May 12, 2016Date of Patent: June 9, 2020Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van Der Graaf, Robert Henk Henning, Leo Edwin Deelman, Gerrit Jan Willem Euverink
-
Patent number: 10426771Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug deliver devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl) (piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: GrantFiled: January 26, 2018Date of Patent: October 1, 2019Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Patent number: 10322124Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: GrantFiled: January 26, 2018Date of Patent: June 18, 2019Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Publication number: 20180280384Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug deliver devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl) (piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: January 26, 2018Publication date: October 4, 2018Applicant: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Publication number: 20180250294Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: January 26, 2018Publication date: September 6, 2018Applicant: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Publication number: 20180170892Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.Type: ApplicationFiled: May 12, 2016Publication date: June 21, 2018Applicant: Sulfateq B.V.Inventors: Adrianus Cornelis VAN DER GRAAF, Robert Henk HENNING, Leo Edwin DEELMAN, Gerrit Jan Willem EUVERINK
-
Patent number: 9913841Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-di-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: GrantFiled: June 17, 2015Date of Patent: March 13, 2018Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Publication number: 20170151234Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-di-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: May 17, 2015Publication date: June 1, 2017Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Publication number: 20130203830Abstract: The invention is related to compounds for prevention of cell injury or protection of cells. The compounds are involved in the maintenance or the increase of hydrogen sulphide in cells, which results in a protection of the cells or the prevention of cell injury. The compounds of the invention can be used in cell culture and tissue culture techniques. They can also be used in several medical conditions such as ischemia, reperfusion and hypothermia, or for preserving organs which are used for transplantation.Type: ApplicationFiled: April 18, 2011Publication date: August 8, 2013Applicant: SULFATEQ B.V.Inventors: Fatemeh Talaei, Robert Henk Henning, Adrianus C. Van der Graaf
-
Publication number: 20080161258Abstract: The invention relates to the field of biology, molecular biology and medicine More specifically, the invention relates to a method for at least in part preventing or delaying or decreasing damage to a cardiac cell induced by a supraventricular arrhythmia. The invention provides a method for preventing, delaying or decreasing damage to a cardiac cell induced by a supraventricular arrhythmia comprising increasing the amount of at least one heat shock protein (HSP) or a functional equivalent and/or a functional fragment thereof, e.g. HSP27 or its functional equivalent HSP25, in said cardiac cell.Type: ApplicationFiled: December 9, 2005Publication date: July 3, 2008Inventors: Robert Henk Henning, Harm Harmannus Kampinga, Bianca Johanna Josephina Maria Brundel
-
Patent number: 7335490Abstract: Provided are uses of erythropoietin, or a derivative or functional analogue thereof, for the production of a medicament for the preventive or curative treatment of patients suffering from, or at risk of suffering from, cardiac failure.Type: GrantFiled: January 9, 2003Date of Patent: February 26, 2008Assignees: Crucell Holland B.V., Stichting Klinische Farmacologie GroningenInventors: Wiekert Hendrikus Van Gilst, Ronald Hendrik Peter Brus, Dirk Jan Van Veldhuisen, Robert Henk Henning, Rudolf Allert De Boer
-
Publication number: 20030073237Abstract: Nucleic acid delivery vehicles for enhancing and/or inducing angiogenesis are provided. The delivery vehicles comprise a nucleic acid encoding angiotensin 1-7 or a functional part, derivative and/or analogue thereof. The vehicles are among others suited for the treatment of heart failure.Type: ApplicationFiled: July 3, 2002Publication date: April 17, 2003Inventors: Antonius Jacobus M. Roks, Yigal-Martin Pinto, Robert Henk Henning, Wiekert Hendrikus van Gilst